Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection
Phase 1
Recruiting
- Conditions
- Respiratory Infections, Recurrent, ChronicCystic Fibrosis LungPseudomonas Aeruginosa
- Interventions
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Respirion Pharmaceuticals Pty Ltd
- Target Recruit Count
- 72
- Registration Number
- NCT06016088
- Locations
- 🇺🇸
Tucson Cystic Fibrosis Center, Tucson, Arizona, United States
🇺🇸Center for Cystic Fibrosis at Keck Medical Center of USC, Los Angeles, California, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
News
No news found